Impact of Human Recombinant Erithoropoietin (ior EPOCIM) in cancer patients with post Chemo and Radiotherapy induced anemia. |
Impact of Recombinant Human Erythropoietin (ior EPO-CIM) in oncology pediatric patients with post chemo and /or radiotherapy. |
Impact of the Granulocytes Colony-Stimulating Factor (ior-LeukoCIM) in primary and secondary prophylaxis and post chemotherapy and/or radiotherapy neutropenia in oncohematological pediatric patients. |
InCarbacel-II |
InCCNM -I |
InCroMiel I |
INJURE Study |
InMuMyel I Study |
Inmunogenicity-PCV-Carriage-Venezuelan High Risk Children |
Insufflation with CO2 versus room air in colonoscopy |
Interferon Combination in basal cell carcinoma (InCarbacel-IV study) |
Interferon Combination in basal cell carcinoma (InCarbacel-V study) |
Intraoperative endoscopic retrograde sphincterotomy as a modality of treatment of choledocholithiasis |
Intravenous CIGB-128-A in patients with brain tumors (BRATINC Study) |
ior EPOCIM ® in the management of anemia of the preterm infant.Phase IV. |
ior ®EPOCIM as a cardioprotective agent in the surgery of rheumatic valvular disease. |
iorEPOCIM-Stroke-Phase I |
ior®EPOCIM in post-COVID-19 convalescent patients with cardiovascular, renal and/or respiratory disorders |
Itolizumab (T1h) combined with insulin in patients with Type I Diabetes Mellitus |
Itolizumab for Moderate-to-Severe Psoriasis-phase 3 |